Methylphenidate prodrug - KemPharm

Drug Profile

Methylphenidate prodrug - KemPharm

Alternative Names: D-threo-methylphenidate prodrug - KemPharm; KP 415; KP 484; Methylphenidate-prodrug-KemPharm

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KemPharm
  • Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine release stimulants; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 14 Mar 2018 KemPharm plans a phase III trial of KP 415 for Attention-deficit hyperactivity disorder (In children) in March 2018 (NCT03460652)
  • 01 Dec 2017 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT03292952)
  • 02 Nov 2017 US FDA approves IND application for KP 484 in Attention deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top